Stockscreener 앱 받기
6.38
0.00%
0.00
시간 외 거래:
6.38
전일 마감가:
$6.38
열려 있는:
$6.38
하루 거래량:
2.44M
Relative Volume:
0.54
시가총액:
$1.23B
수익:
$71.80M
순이익/손실:
$-183.59M
주가수익비율:
-6.0514
EPS:
-1.0543
순현금흐름:
$-186.52M
1주 성능:
+3.91%
1개월 성능:
-11.14%
6개월 성능:
-16.82%
1년 성능:
+7.23%
1일 변동 폭
$6.225
$6.44
1주일 범위
$6.02
$6.4999
52주 변동 폭
$5.02
$21.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
명칭
Wave Life Sciences Ltd
전화
617-949-2900
주소
7 STRAITS VIEW, SINGAPORE
Compare WVE vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
WVE
Wave Life Sciences Ltd
|
6.38 | 1.23B | 71.80M | -183.59M | -186.52M | -1.0543 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-05 | 개시 | BofA Securities | Buy |
| 2025-12-12 | 재확인 | Wedbush | Outperform |
| 2025-12-09 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-08-04 | 개시 | Canaccord Genuity | Buy |
| 2025-07-28 | 개시 | Oppenheimer | Outperform |
| 2025-07-16 | 개시 | Citigroup | Buy |
| 2025-06-11 | 재개 | Raymond James | Outperform |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-08 | 개시 | Wedbush | Outperform |
| 2025-02-25 | 개시 | Jefferies | Buy |
| 2024-10-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-09-27 | 재개 | JP Morgan | Overweight |
| 2024-09-19 | 개시 | B. Riley Securities | Buy |
| 2024-09-09 | 개시 | JP Morgan | Overweight |
| 2024-05-15 | 개시 | Wells Fargo | Overweight |
| 2023-12-19 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | 개시 | Raymond James | Outperform |
| 2023-05-24 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-15 | 재개 | H.C. Wainwright | Buy |
| 2020-10-23 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-31 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-11-01 | 개시 | Guggenheim | Buy |
| 2019-07-15 | 개시 | Cowen | Market Perform |
| 2019-04-17 | 재확인 | H.C. Wainwright | Buy |
| 2018-08-07 | 개시 | Stifel | Buy |
| 2018-07-23 | 개시 | H.C. Wainwright | Buy |
| 2018-03-19 | 재확인 | Mizuho | Buy |
| 2017-02-15 | 개시 | H.C. Wainwright | Buy |
| 2016-11-10 | 재개 | Leerink Partners | Outperform |
| 2015-12-07 | 개시 | JMP Securities | Mkt Outperform |
| 2015-12-07 | 개시 | Jefferies | Buy |
| 2015-12-07 | 개시 | Leerink Partners | Outperform |
| 2015-12-07 | 개시 | Sun Trust Rbsn Humphrey | Buy |
모두보기
Wave Life Sciences Ltd 주식(WVE)의 최신 뉴스
Should WVE-006’s RNA-Editing AAT Data Shift the Risk-Reward Calculus for Wave Life Sciences (WVE) Investors? - Yahoo Finance
Wave Life Sciences (WVE) Valuation Check After Sharp Share Price Weakness - simplywall.st
WAVE Life Sciences Analyst Ratings and Price Targets | NASDAQ:WVE - Benzinga
WVE Stock Price, Quote & Chart | WAVE LIFE SCIENCES LTD (NASDAQ:WVE) - ChartMill
Wells Fargo Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Wave Life Sciences (WVE) Is Down 11.4% After Positive WVE-006 AATD Data and Accelerated Path Update - simplywall.st
Wave Life Sciences: 'Strong Buy' On DMD NDA Filing WVE-N531 And Released AATD Data - Seeking Alpha
WVE Maintained by Wells Fargo -- Price Target Raised to $14.00 - GuruFocus
Wave Life Sciences Is Maintained at Overweight by Wells Fargo - Moomoo
CCORF Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $43 - Moomoo
WVE: Advancing siRNA and RNA editing therapies with strong clinical data and regulatory momentum - TradingView
Wells Fargo raises Wave Life Sciences price target on AATD data - Investing.com Australia
Wells Fargo Maintains Wave Life Sciences(WVE.US) With Buy Rating, Cuts Target Price to $14 - Moomoo
Wave Life Sciences Signals Momentum in Earnings Call - TipRanks
Wave Life Sciences crashes deep into oversold territory as obesity drug data disappoints. Should you buy the dip? - MSN
WVE Maintained by HC Wainwright & Co. -- Price Target Lowered to $13 - GuruFocus
Wave Life Sciences' New Data From AATD Study Met Expectations, Wedbush Says - Moomoo
Cantor Fitzgerald reiterates Overweight on Wave Life Sciences stock By Investing.com - Investing.com South Africa
Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1 - Yahoo Finance UK
A Quick Look at Today's Ratings for Wave Life Sciences(WVE.US), With a Forecast Between $13 to $15 - Moomoo
Wave Life Sciences stock price target lowered to $13 by H.C. Wainwright - Investing.com South Africa
Cantor Fitzgerald reiterates Overweight on Wave Life Sciences stock - Investing.com
H.C. Wainwright Maintains Wave Life Sciences(WVE.US) With Buy Rating, Cuts Target Price to $13 - Moomoo
Wave Life Sciences Announces Positive RestorAATion-2 Trial Results for WVE-006, a Novel RNA Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD) - Minichart
Wave Life Sciences Ltd. (WVE) Shareholder/Analyst CallSlideshow (NASDAQ:WVE) 2026-05-18 - Seeking Alpha
WVE: WVE-006 delivers robust Z-AAT reduction and M-AAT restoration with strong safety in PiZZ AATD - TradingView
Wave Life Sciences reports phase 1b/2a trial data for AATD therapy By Investing.com - Investing.com South Africa
WVE: WVE-006 delivers robust, durable AAT correction and dynamic response in ZZ AATD with strong safety - TradingView
WVE Stock Edges Up After Positive Early Data For Rare Disease Drug - Stocktwits
WVE: WVE-006 achieved up to 71% Z-AAT reduction and restored protective M-AAT levels in AATD - TradingView
Wave Life Sciences advances WVE-006 RNA editing trial - TipRanks
Wave Life Sciences (WVE) Reports Progress on WVE-006 in Clinical Trial - GuruFocus
Wave Life Sciences reports phase 1b/2a trial data for AATD therapy - Investing.com
Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing - TradingView
WVE-006 AATD trial shows strong biomarker gains for Wave Life Sciences (WVE) - Stock Titan
Wave Life Sciences Reports Promising Data for WVE-006 in Treating Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency, Anticipates FDA Feedback in Mid-2026 - Quiver Quantitative
Experimental RNA-editing shot aims to treat lung and liver damage in alpha-1 - Stock Titan
Wave Life Sciences (WVE) price target decreased by 15.26% to 23.97 - MSN
Wave Life Sciences Ltd.Ordinary Shares (NQ: WVE - FinancialContent
Wedbush Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Wave Life Sciences ATS Data Could Support RNA Editing Platform, Wedbush Says - Moomoo
Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight - GlobeNewswire Inc.
Wave Life Sciences stock (SG1V20936237): Starts Phase 1 trial for one-time GLP-1 gene therapy - AD HOC NEWS
Wave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare Conference - The Manila Times
Adage (NASDAQ: WVE) discloses 1,000,000-share stake, 0.53% of class - Stock Titan
Wave Life Sciences (WVE) Attracts Positive Attention Amid Compet - GuruFocus
Surging Q1 Revenue And Narrower Losses Might Change The Case For Investing In Wave (WVE) - Sahm
Wave Life Sciences Ltd (WVE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):